Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2013 1
2014 2
2016 1
2017 1
2018 5
2019 2
2020 4
2021 4
2022 6
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Net survival of men with localized prostate cancer after LDR brachytherapy.
Uribe-Lewis S, Uribe J, Deering C, Langley S, Higgins D, Whiting D, Metawe M, Khaksar S, Mehta S, Mikropoulos C, Otter S, Perna C, Langley S. Uribe-Lewis S, et al. Among authors: mikropoulos c. Brachytherapy. 2024 Mar 26:S1538-4721(24)00039-4. doi: 10.1016/j.brachy.2024.02.006. Online ahead of print. Brachytherapy. 2024. PMID: 38538414
Prognostic Factors in Patients with Metastatic Spinal Cord Compression Secondary to Lung Cancer-A Retrospective UK Single-Centre Study.
Vassiliou A, Osunronbi T, Enyioma S, Rago G, Karathanasi A, Ghose A, Sheriff M, Mikropoulos C, Sanchez E, Moschetta M, Chargari C, Rassy E, Boussios S. Vassiliou A, et al. Among authors: mikropoulos c. Cancers (Basel). 2023 Sep 6;15(18):4432. doi: 10.3390/cancers15184432. Cancers (Basel). 2023. PMID: 37760402 Free PMC article.
State-of-the-Art Molecular Oncology in UK.
Sandoughdaran S, Mikropoulos C, Boussios S. Sandoughdaran S, et al. Among authors: mikropoulos c. Int J Mol Sci. 2023 May 26;24(11):9336. doi: 10.3390/ijms24119336. Int J Mol Sci. 2023. PMID: 37298288 Free PMC article.
Serum testosterone and prostate cancer in men with germline BRCA1/2 pathogenic variants.
Dias A, Brook MN, Bancroft EK, Page EC, Chamberlain A, Saya S, Amin J, Mikropoulos C, Taylor N, Myhill K, Thomas S, Saunders E, Dadaev T, Leongamornlert D, Dyrsø Jensen T, Evans DG, Cybulski C, Liljegren A, Teo SH, Side L; IMPACT study collaborators and Steering Committee; Kote-Jarai Z, Eeles RA. Dias A, et al. Among authors: mikropoulos c. BJUI Compass. 2023 Jan 9;4(3):361-373. doi: 10.1002/bco2.156. eCollection 2023 May. BJUI Compass. 2023. PMID: 37025481 Free PMC article.
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Brown JE, Royle KL, Gregory W, Ralph C, Maraveyas A, Din O, Eisen T, Nathan P, Powles T, Griffiths R, Jones R, Vasudev N, Wheater M, Hamid A, Waddell T, McMenemin R, Patel P, Larkin J, Faust G, Martin A, Swain J, Bestall J, McCabe C, Meads D, Goh V, Min Wah T, Brown J, Hewison J, Selby P, Collinson F; STAR Investigators. Brown JE, et al. Lancet Oncol. 2023 Mar;24(3):213-227. doi: 10.1016/S1470-2045(22)00793-8. Epub 2023 Feb 13. Lancet Oncol. 2023. PMID: 36796394 Free article. Clinical Trial.
30 results